Literature DB >> 18942074

Malignant abdominal mesothelioma: defining the role of surgery.

Dayron Rodríguez1, Michael C Cheung, Nadine Housri, Leonidas G Koniaris.   

Abstract

OBJECTIVE: Determine the role of surgery for patients with malignant abdominal mesotheliomas (MAMs).
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (1973-2005) was queried.
RESULTS: Overall, 10,589 cases of malignant mesotheliomas were identified. Of these, 9,211 cases were thoracic (TM) and 1,112 cases were MAM (10.5%). Patients with TM presented with more localized disease than those patients with MAM (P < 0.001). MAM more often affected younger patients (63 years vs. 71 years) (P < 0.001). The annual incidence of MAM was approximately 1.00 case per 100,000 in 2005. Overall median survival for MAM patients was 8 months, with a significant difference between women and men (13 months vs. 6 months, respectively) (P < 0.001). Patients who successfully underwent surgical resection had a considerably longer median survival (20 months vs. 4 months, P < 0.001) as well as a significantly higher 5-year survival (28% vs. 12%, P < 0.001). Multivariate analysis identified that a poorly differentiated tumor grade, failure to undertake surgical resection, advanced age, and male gender were all independent predictors of poorer outcome.
CONCLUSION: Surgical extirpation of MAM may be associated with significantly improved survival. All patients with MAM should be evaluated for potential surgical resection.

Entities:  

Mesh:

Year:  2009        PMID: 18942074     DOI: 10.1002/jso.21167

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  24 in total

1.  The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking.

Authors:  Samer A Naffouje; Kiara A Tulla; George I Salti
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

Review 2.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 3.  Diffuse malignant epithelioid mesothelioma in a background of benign multicystic peritoneal mesothelioma: a case report and review of the literature.

Authors:  Jeffrey S Mino; Rosebel Monteiro; Rodolfo Pigalarga; Sumi Varghese; Laura Guisto; Craig Rezac
Journal:  BMJ Case Rep       Date:  2014-02-05

4.  Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.

Authors:  Julie Dragon; Joyce Thompson; Maximilian MacPherson; Arti Shukla
Journal:  J Cell Biochem       Date:  2015-08       Impact factor: 4.429

5.  Advanced diffuse malignant peritoneal mesothelioma responding to palliative chemotherapy.

Authors:  Koji Nakashima; Haruhiko Inatsu; Kazuo Kitamura; Tomomi Hikosaka; Shinri Hoshiko; Shinya Ashiduka
Journal:  Clin J Gastroenterol       Date:  2012-10-17

6.  A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis.

Authors:  Hirokazu Saito; Shota Hasuda; Jiro Nasu; Mitsuhiko Kitaoka; Ikuo Matsushita
Journal:  Clin J Gastroenterol       Date:  2017-06-23

Review 7.  Update on the management of malignant peritoneal mesothelioma.

Authors:  Paul H Sugarbaker
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 8.  Advances in the management of peritoneal mesothelioma.

Authors:  Ali Raza; Wei-Ching Huang; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

9.  Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Authors:  Tomoko Akahane; Akira Hirasawa; Issei Imoto; Aki Okubo; Manabu Itoh; Yoshiko Nanki; Tomoko Yoshihama; Eichiro Tominaga; Daisuke Aoki
Journal:  Hum Cell       Date:  2019-10-03       Impact factor: 4.174

10.  Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.

Authors:  Gauri R Varadhachary; Daniel M Halperin; Kanwal Raghav; Suyu Liu; Michael J Overman; Anneleis F Willett; Mark Knafl; Szu-Chin Fu; Anais Malpica; Seema Prasad; Richard E Royal; Christopher P Scally; Paul F Mansfield; Ignacio I Wistuba; Andrew P Futreal; Dipen M Maru; Luisa M Solis Soto; Edwin R Parra Cuentas; Honglei Chen; Pamela Villalobos; Anuj Verma; Armeen Mahvash; Patrick Hwu; Patricia Cortazar; Edward McKenna; Cindy Yun; Shannon Dervin; Katja Schulze; Walter C Darbonne; Ajaykumar C Morani; Scott Kopetz; Keith F Fournier; Scott E Woodman; James C Yao
Journal:  Cancer Discov       Date:  2021-07-14       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.